Wordt geladen...
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...
Bewaard in:
| Gepubliceerd in: | Hum Vaccin Immunother |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7012081/ https://ncbi.nlm.nih.gov/pubmed/31343949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1632683 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|